

#### **SECTION 1: PRODUCT IDENTIFICATION**

PRODUCT NAME AMLODIPINE BESYLATE, USP

PRODUCT CODE 2734

SUPPLIER

MEDISCA Inc.

Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063

MEDISCA Pharmaceutique Inc.

Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8

21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2

**MEDISCA Australia PTY LTD** 

Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047

Unit 7, Heritage Business Park

5-9 Ricketty Street, Mascot, NSW 2020

EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300

NSW Poisons Information Centre: 131 126

National Chemical Emergency Centre 44(0)1235239670

RECOMMENDED USES Manufacturing and Compounding

RESTRICTIONS ON USE Not applicable

#### **SECTION 2: HAZARDS IDENTIFICATION**

GHS CLASSIFICATION Acute Toxicity - Oral (Category 4)

Eye Irritation (Category 2A)
Acute Aquatic Toxicity (Category 1)

**PICTOGRAM** 

(!)

Warning



SIGNAL WORD

HAZARD STATEMENT(S) Exposure may produce an allergic reaction.

Harmful if swallowed.
Causes skin irritation.
Causes serious eye irritation.
Very toxic to aquatic life.
May cause dizziness.

ADVERSE PHYSIOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL EFFECTS Not Applicable.



PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Do not touch eyes.

Do not eat, drink or smoke when using this product.

Wear protective gloves, eye and face protection.

Avoid release to the environment.

Response IF SWALLOWED: Immediately call a poison center. Get medical help. Rinse mouth.

IF ON SKIN (HAIR): Wash with plenty of water. If skin irritation occurs: Get medical

advice/attention. Take off contaminated clothing and wash it before reuse.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical help.

**COLLECT SPILLAGE** 

Storage Not applicable.

**Disposal** Dispose of contents and/or container in accordance with local regulations.

HMIS CLASSIFICATION Health Hazard 2 Flammability 0

Reactivity 0 Personal Protection F

#### SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

CHEMICAL NAME

3-Ethyl 5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-

(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulfonate

BOTANICAL NAME Not applicable

SYNONYM Amlodipine Besilate; Amlodipine Benzenesulfonate

CHEMICAL FORMULA C<sub>20</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>5</sub>·C<sub>6</sub>H<sub>6</sub>O<sub>3</sub>S

CHEMICAL FAMILY Dihydropyridine calcium channel blocker

CAS NUMBER 111470-99-6
ALTERNATE CAS NUMBER Not applicable
MOLECULAR WEIGHT 567.0559

OLECULAR WEIGHT

CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT
AMLODIPINE BESYLATE	111470-99-6	601-097-8	100

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

#### **SECTION 4: FIRST-AID MEASURES**

IN CASE OF EYE CONTACT Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek

medical aid.

IN CASE OF SKIN CONTACT

Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a

physician

MEDICAL ATTENTION AND SPECIAL

TREATMENT

COMPOSITION

Get emergency medical help.

SYMPTOMS CAUSED BY EXPOSURE Not expected to present a significant hazard under anticipated conditions of normal use.

Last Revision: 02/2023 AMLODIPINE BESYLATE, USP Page 2 of 8



#### **SECTION 5: FIREFIGHTING MEASURES**

SPECIFIC HAZARDS ARISING FROM

THE CHEMICAL

Strong potential for dust explosion.

Dust explosion properties:

Kst: 233 bar.m/s St class: 2

Minimum ignition energy (MIE) - dust cloud: 9 - 18 mJ

**FLAMMABLE PROPERTIES** 

May be combustible at high temperature

HAZARDOUS COMBUSTION PRODUCTS

rs u

Under fire conditions, hazardous fumes will be present.

SUITABLE & UNSUITABLE EXTINGUISHING MEDIA

Small fire: dry chemical, CO<sub>2</sub> or water spray. Large fire: dry chemical, CO<sub>2</sub>, alcohol resistant foam or water spray. Do not get water inside containers.

PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

#### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

PERSONAL PRECAUTIONS Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate

ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

METHODS & MATERIAL FOR

CONTAINMENT

**CLEANUP PROCEDURE** 

On land, sweep or shovel into suitable containers. Minimize generation of dust.

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean

the affected area. Do not flush into sewerage system or to drains.

REFERENCE TO OTHER SECTIONS See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment.

See Section 13 for disposal information.

#### **SECTION 7: HANDLING AND STORAGE**

PRECAUTIONS FOR SAFE HANDLING Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash

thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use

appropriate containment to avoid environmental contamination.

CONDITIONS FOR SAFE STORAGE

Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened

must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid

environmental contamination.

STORAGE CONDITIONS Store in original container, tightly sealed, protected from direct sunlight and moisture.

Short term excursions, temperature excursions as experienced during shipping and warehousing, up to 40 °C are acceptable.

### **SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION**

Last Revision: 02/2023 AMLODIPINE BESYLATE, USP Page 3 of 8



#### 

	Country	Limit value-8 hours		ours Limit value-Short Term		IDLH REL	Advisory	Notes	
		ppm	mg/m³	ppm	mg/m³				
OSHA	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
ACGIH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
NIOSH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
WEEL	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSIS	Australia	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSE	UK	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
GESTIS	Add Country	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

N/L = Not listed; N/A = Not Available

PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

EXPOSURE GUIDELINES Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable

fraction: 5 mg/m3.

PERSONAL PROTECTIVE EQUIPMENT Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's

eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to minimize contact with skin. Respirators: Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Thermal Hazards: For products representing a

thermal hazard, appropriate Personal Protective Equipment should be used.

SPECIFIC ENGINEERING CONTROLS Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

**BIOLOGICAL MONITORING** Not available CONTROL BANDING Not available

**NOTES** USP recommended TWA: 0.1 mg/m3 (base)

#### **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

PHYSICAL STATE Solid

DESCRIPTION White or almost white powder.

SOLUBILITY Slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, slightly soluble in 2-propanol.

ODOR	Not available									
FLAMMABILITY	May be combustible at high temperature									
AUTO-IGNITION TEMPERATURE	Not available	BOILING POINT	Not available	DECOMPOSITION TEMPERATURE	Not available					
EVAPORATION RATE	Not available	EXPLOSIVE LIMIT	Not available	FLASH POINT	Not available					
log P (OCTANOL-WATER)	2.759 (20°C, pH 7)	LOWER FLAMMABLE/ EXPLOSIVE LIMIT(S)	Not available	MELTING/FREEZING POINT	(199 - 203)°C, (390.2-397.4)°F					



OXIDIZING PROPERTY **PARTICLE** Not available Not available Not available pΗ **CHARACTERISTICS** UPPER FLAMMABLE/ RELATIVE DENSITY Not available SPECIFIC GRAVITY Not available Not available (WATER = 1) **EXPLOSIVE LIMIT(S)** VAPOR DENSITY Not available VAPOR PRESSURE Not available VISCOSITY Not available (AIR = 1)

The physical data presented above are typical values and should not be construed as a specification.

#### **SECTION 10: STABILITY AND REACTIVITY**

REACTIVITY Not established

CHEMICAL STABILITY Stable under recommended storage conditions

INCOMPATIBLE MATERIALS Strong oxidants

HAZARDOUS DECOMPOSITION

PRODUCTS

Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur

HAZARDOUS POLYMERIZATION Will not occur
POSSIBLITY OF HAZARDOUS Not established

REACTION

CONDITIONS TO AVOID

Moisture, sunlight and extreme temperatures. Heat and sources of ignition.

#### **SECTION 11: TOXICOLOGICAL INFORMATION**

ACUTE TOXICITY Oral: Rat: LD50: (mg/kg): 393 - 686

Dermal: Rabbit: LD50: (mg/kg): Not available Inhalation: Rat: LC50: (mg/L/4hr): Not available

SKIN CORROSION/IRRITATION Based on available data, the classification criteria are not met.

SERIOUS EYE DAMAGE/EYE Causes serious eye irritation.

IRRITATION

Direct contact may result in corneal injury. Redness, pain.

**RESPIRATORY SENSITIZATION**Due to lack of data the classification is not possible.

SKIN SENSITIZATION Due to lack of data classification is not possible.

GERM CELL MUTAGENICITY

Due to lack of data classification is not possible.

Data from germ cell mutagenicity tests were not found. Other mutagenicity tests did not indicate that

Amilodipine besylate is mutagenic.

CARCINOGENICITY OSHA AMLODIPINE BESYLATE is not listed.

NTP AMLODIPINE BESYLATE is not listed.

IARC AMLODIPINE BESYLATE is not evaluated.

California This product does not contain any chemicals known to the State of California to cause

**Proposition 65** cancer, birth defects, or any other reproductive harm.



ADDITIONAL CARCINOGENICITY

INFORMATION

Carcinogenicity study: Mouse: 0.5 mg/kg/day: No evidence of carcinogencity. Carcinogenicity study: Rat: 2.5 mg/kg/day: No evidence of carcinogencity.

Based on available data, the classification criteria are not met.

Suspected carcinogen: The Toolbox profiler Carcinogenicity (genotox and nongenotox) alerts by ISS gives an

alert for carcinogenicity

REPRODUCTIVE TOXICITY

Based on available data, the classification criteria are not met.

In animals, many of the processes of embryogenesis appear to be calcium-dependent, and there are theoretical concerns about use of calcium channel blockers by humans in early pregnancy. However, epidemiological studies have not shown an association between therapeutic use of calcium channel blocking agents during

pregnancy and an increased incidence of birth defects.

 $Reproductive \ and \ development \ study: \ Rat: \ Oral: \ 25 \ mg/kg/day: \ Maternal \ toxicity, \ but \ no \ fetotoxicity, \ development \ study: \ Rat: \ Oral: \ 25 \ mg/kg/day: \ Maternal \ toxicity, \ but \ no \ fetotoxicity, \ development \ study: \ Rat: \ Oral: \ Rat$ 

embryotoxicity or teratogenicity noted.

Reproductive and development study: Rabbit: Oral: 25 mg/kg/day: No fetotoxicity, embryotoxicity or

teratogenicity noted.

SPECIFIC TARGET ORGAN TOXICITY -

SINGLE EXPOSURE

Based on available data, the classification criteria are not met.

SPECIFIC TARGET ORGAN TOXICITY -

REPEATED EXPOSURE

Based on available data, the classification criteria are not met.

**ASPIRATION HAZARDS** 

Based on available data, the classification criteria are not met.

ACT II CHI I PARA I CO

SIGNS AND SYMPTOMS OF

**EXPOSURE** 

ROUTES OF EXPOSURE:

Oral, Dermal, Inhalation, Eyes

EARLY ONSET SYMPTOMS RELATED TO EXPOSURE:

Not available.

DELAYED HEALTH EFFECT FROM EXPOSURE:

Calcium channel blocking agents: Low blood pressure. Pulmonary edema. Cardiac dysrhythmias.

Hyperglycemia. Circulatory problems. Metabolic acidosis.

Symptoms related to the physical, chemical, and toxicological characteristics:

Calcium channel blocking agents: Dizziness. Tiredness. Headache. Sleep disturbances. Fast, pounding, slow, or irregular heartbeat. Swelling of legs. Weakness. Muscle cramps. Flushing. Nausea. Heartburn. Constipation.

Diarrhea. Skin rash. Itching. Swollen or bleeding gums. Coughing. Difficulty breathing. Sore throat.

Medical conditions aggravated by exposure:

Calcium channel blocking agents: Heart failure. Kidney disease. Liver disease. Blood vessel disorders.

Gastroesophageal reflux. Hypotension. Peripheral edema. Diabetes.

POTENTIAL HEALTH EFFECTS

**Inhalation** May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion May be harmful if swallowed. Gastrointestinal disorders. Burns to the gastric/intestinal

nucosa.

**Skin** May be harmful if absorbed through skin. Causes skin irritation. Redness, pain.

Eyes Causes serious eye irritation. Direct contact may result in corneal injury. Redness, pain.

#### **SECTION 12: ECOLOGICAL INFORMATION**

ECOTOXICITY EC50: 48 Hr: Crustacea: Daphnia magna (mg/L): 3.2

LC50: 96 Hr: Fish: (mg/L): 14 EC50: 72 Hr: Algae: (mg/L): 0.28

PERSISTENCE AND DEGRADABILITY

Not available

BIOACCUMULATIVE POTENTIAL

Log Pow: 2.759 (20°C, pH 7).

**MOBILITY IN SOIL** 

Slightly soluble in water

OTHER ADVERSE EFFECTS

Not available

This product is not intended to be released into the environment

Last Revision: 02/2023 AMLODIPINE BESYLATE, USP Page 6 of 8



### **SECTION 13: DISPOSAL CONSIDERATIONS**

DISPOSAL METHODS Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

#### **SECTION 14: TRANSPORT INFORMATION**

UN PROPER SHIPPING NAME ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

UN NUMBER 3077
CLASS 9
PACKING GROUP III

<u>AUSTRALIA</u>

HAZCHEM 2Z

ΕU

TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE

IBC CODE

Not listed

ENVIRONMENTAL HAZARDS Not available SPECIAL SHIPPING INFORMATION Not applicable

### **SECTION 15: REGULATORY INFORMATION**

#### **UNITED STATES REGULATIONS**

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR Part 372.65	EPA 40 CF Appendix A	FR Part 355 Appendix B	Pennsylvania	Right-to-know New Jersey	Massachusetts	California Prop 65
AMLODIPINE BESYLATE	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L
111470-99-6								

N/L = Not Listed; X = Listed

#### **AUSTRALIAN REGULATIONS**

Chemical Name & CAS	Poisons and Therapeutic Goods	Therapeutic Goods Act	Code of Practices - Illicit Drug Precursors	Poisons Standard	Work Health and Safety Regulations	Inventory of Industrial Chemcials
AMLODIPINE BESYLATE 111470-99-6	N/L	Listed as Schedule	N/L	Listed	N/L	N/L

N/L = Not Listed

#### **EU REGULATIONS**



C	Chemical Name & CAS	REACH ANNEX XVII	REACH ANNEX XIV	EC 1005/2009	EC 850/2004	EC 1107/2009	PIC - Prior Informed Consent Regulation	EC 2012/18
AMLC	DDIPINE BESYLATE 111470-99-6	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

SUBJECT TO INTERNATIONAL

Not applicable

**AGREEMENT** 

#### **SECTION 16: OTHER INFORMATION**

REFERENCES

ABBREVIATIONS AND ACRONYMS

Available upon request

ACGIH - American Conference of Governmental Industrial Hygienists; AIHA WEEL - American Industrial Hygiene Association Workplace Environment Exposure Levels; CAESAR - Computer Assisted Evaluation of industrial chemical Substances According to Regulations; CAS - Chemical Abstract Service; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; EC50 - Effective Concentration, 50%; EPA - Environmental Protection Agency; GHS - Global Harmonized System; HMIS - Hazardous Materials Information System; HSE - Health and Safety Executive; HSIS - Hazardous Substances Information System; IARC - International Agency for Research on Cancer; IDLH - Immediately Dangerous to Life or Health; IRFMN - Ready Biodegradability Model; ISS - Instituto Superiore Sanità; LC50 - Lethal Concentration, 50%; LD50 - Lethal Dose, 50%; MSHA - Mine Safety and Health Administration; NIOSH - National Institute for Occupational Safety and Health; NTP - National Toxicology Program; OSHA PEL - Occupational Safety & Health Administration Permissible Exposure Limits; QSAR - Quantitative Structure-activity relationship; REL - Recommended Exposure Limit; SARA - Superfund Amendments and Reauthorization Act; STEL - Short Term Exposure Limit; TLV - Threshold Limit Value; TWA - Time Weighted Average; WHMIS - Workplace Hazardous Materials Information System

LAST REVISION SUPERSEDES 02/2023

04/2021

For a list of changes to the SDS since the last version, please communicate with MEDISCA at <a href="https://www.medisca.com">www.medisca.com</a>

DISCLAIMER

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

SUPPLEMENTARY INFORMATION

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.